[go: up one dir, main page]

PE20030336A1 - Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents

Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Info

Publication number
PE20030336A1
PE20030336A1 PE2002000807A PE2002000807A PE20030336A1 PE 20030336 A1 PE20030336 A1 PE 20030336A1 PE 2002000807 A PE2002000807 A PE 2002000807A PE 2002000807 A PE2002000807 A PE 2002000807A PE 20030336 A1 PE20030336 A1 PE 20030336A1
Authority
PE
Peru
Prior art keywords
indan
ona
alkyl
chloro
obesity
Prior art date
Application number
PE2002000807A
Other languages
English (en)
Inventor
Gerhard Jaehne
Volker Krone
Matthias Gossel
Martin Bickel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030336A1 publication Critical patent/PE20030336A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-ONA SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, N3, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, ENTRE OTROS; X ES S, SO, SO2, Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)rCOR6, CH2-CH(NHR7)-COR8, FENILO, ; r ES 1-6; R6 ES OH, O-ALQUILO C1-C6, NH2, CH2-CH(NHR7)-COR8; R7 ES H, CO-ALQUILO C1-C4, COO-ALQUILO C1-C4; R8 ES OH, O-ALQUILO C1-C6, NH2 PARA LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE OBESIDAD. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFANIL-INDAN-1-ONA; 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA; 5-CLORO-2-FENILSULFANIL-INDAN-1-ONA, 2-BENCENOSULFONIL-5-CLORO-INDAN-1-ONA, 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA. TAMBIEN SE REFIERE AL USO CON CATINA, FENILPROPANOLAMINA, AMFEPRAMONA, MEFENOREX, EFEDRINA, LEPTINA, DEXANFETAMINA, ANFETAMINA, ENTRE OTROS
PE2002000807A 2001-08-31 2002-08-22 Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad PE20030336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142668A DE10142668A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
PE20030336A1 true PE20030336A1 (es) 2003-05-19

Family

ID=7697238

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000807A PE20030336A1 (es) 2001-08-31 2002-08-22 Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Country Status (10)

Country Link
US (1) US6946492B2 (es)
EP (1) EP1424999A1 (es)
JP (1) JP4342306B2 (es)
AU (1) AU2002336985B2 (es)
CA (1) CA2458555A1 (es)
DE (1) DE10142668A1 (es)
IL (2) IL160607A0 (es)
MX (1) MXPA04001853A (es)
PE (1) PE20030336A1 (es)
WO (1) WO2003020256A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010206549B2 (en) * 2009-01-26 2016-08-25 Dcb-Usa, Llc Use of pterosin compounds for treating diabetes and obesity
CN103333144B (zh) * 2013-06-17 2014-12-10 温州大学 一种2-硫基-3-卤代苯并呋喃化合物及其合成方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
RU2073673C1 (ru) * 1987-10-19 1997-02-20 Пфайзер Инк. Рацемические и оптические активные производные тетралина и 7-гидрокситетралина
EP0873301B1 (en) * 1995-12-06 2004-02-25 Venantius Limited Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity
JP3071832B2 (ja) 1996-01-17 2000-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合した1,2,4−チアジアジン及び縮合した1,4−チアジン誘導体、これらの製造および使用
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
DE60012700T2 (de) * 1999-03-01 2005-07-28 Pfizer Products Inc., Groton Oxamsäure und deren derivate als liganden der thyroid-rezeptoren
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

Also Published As

Publication number Publication date
MXPA04001853A (es) 2004-06-15
JP4342306B2 (ja) 2009-10-14
US20030134882A1 (en) 2003-07-17
JP2005503396A (ja) 2005-02-03
DE10142668A1 (de) 2003-03-20
EP1424999A1 (de) 2004-06-09
IL160607A0 (en) 2004-07-25
CA2458555A1 (en) 2003-03-13
US6946492B2 (en) 2005-09-20
AU2002336985B2 (en) 2006-11-16
IL160607A (en) 2011-03-31
WO2003020256A1 (de) 2003-03-13

Similar Documents

Publication Publication Date Title
PE20021091A1 (es) Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
RU2370485C2 (ru) Амидоацетонитрильные производные
AR038723A1 (es) Cumarinas utiles como biomarcadores
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
ATE381540T1 (de) Oximesther-fotoinitiatoren
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
UY27699A1 (es) Inhibidores.
BRPI0606318B8 (pt) composto, composição, e, uso de um composto
PE20071328A1 (es) Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso
WO2003016291A1 (fr) Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
DE60230546D1 (de) Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
MX9302169A (es) Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CO5140075A1 (es) Agentes terapeuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
DE60312136D1 (de) Radiofluorierungsverfahren
CO5700735A2 (es) Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas
PE20030336A1 (es) Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
RU2009138470A (ru) Композиция для наружного применения на коже
PE20030339A1 (es) Derivados de sistemas de indan-1-oles sustituidos en c2 y procedimiento para su preparacion
AR035481A1 (es) Compuestos de benzosultamoxazolidinona, una composicion farmaceutica, y el uso de dichos compuestos para la manufactura de medicamentos antibacterianos
RU2008102251A (ru) Аналоги тиоколхикозида с миорелаксантной и противовоспалительной активностью
PE20030362A1 (es) Sistemas de indan-1-ol-sustituidos en c2 y procedimiento para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal